BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 16387078)

  • 1. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
    Chen JH; Mao YY; He Q; Wu JY; Lv R
    Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
    Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
    Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients.
    Helantera I; Koskinen P; Tornroth T; Loginov R; Gronhagen-Riska C; Lautenschlager I
    Transplantation; 2003 Jun; 75(11):1858-64. PubMed ID: 12811246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
    Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
    Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
    Stratta RJ; Alloway RR; Lo A; Hodge EE;
    Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G; Daniel V; Naujokat C; Döhler B
    Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
    Potena L; Holweg CT; Chin C; Luikart H; Weisshaar D; Narasimhan B; Fearon WF; Lewis DB; Cooke JP; Mocarski ES; Valantine HA
    Transplantation; 2006 Aug; 82(3):398-405. PubMed ID: 16906040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection.
    Kranz B; Vester U; Wingen AM; Nadalin S; Paul A; Broelsch CE; Hoyer PF
    Pediatr Transplant; 2008 Jun; 12(4):474-8. PubMed ID: 18466436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation.
    Jung GO; Kim SJ; Choi GS; Moon JI; Kim JM; Sin MJ; Kim EY; Kwon CH; Joh JW; Lee SK
    Transplant Proc; 2010 Apr; 42(3):804-10. PubMed ID: 20430177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
    Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
    Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cytomegalovirus disease on early and late renal graft function.
    Boratyńska M; Banasik M; Watorek E; Patrzałek D; Szyber P; Klinger M
    Transplant Proc; 2006; 38(1):147-50. PubMed ID: 16504688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of cytomegalovirus infection and factors causing reactivation of the infection among renal transplant recipients: a single center study.
    Khameneh ZR
    Saudi J Kidney Dis Transpl; 2008 Jan; 19(1):41-5. PubMed ID: 18087121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation.
    Peterson PK; Balfour HH; Marker SC; Fryd DS; Howard RJ; Simmons RL
    Medicine (Baltimore); 1980 Jul; 59(4):283-300. PubMed ID: 6248718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.
    Erdbruegger U; Scheffner I; Mengel M; Schwarz A; Verhagen W; Haller H; Gwinner W
    Nephrol Dial Transplant; 2012 Jan; 27(1):435-43. PubMed ID: 21712490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.